Dissecting the immune evasion and therapeutic resistance mechanisms in EGFR/TP53 co-mutated non-small cell lung cancer: implications for targeted and immunotherapy strategies
These findings reveal a coordinated transcriptional network that promotes immune evasion and therapeutic resistance in EGFR/TP53 co-mutated NSCLC. Targeting the STAT1/ETS1 axis, in combination with EGFR-TKIs or immune checkpoint inhibitors, may provide a novel strategy to overcome resistance and improve patient outcomes. Further validation in larger patient cohorts and functional studies is warranted to confirm these observations and support clinical translation.
Authors
- Minjung Song (ORCID: https://orcid.org/0009-0001-6046-2392)
- Kun Xu (ORCID: https://orcid.org/0000-0003-2773-789X)
- Xueyu Huo
- Ke Gao (ORCID: https://orcid.org/0000-0002-1296-9471)
- Weining Xie (ORCID: https://orcid.org/0000-0002-6048-5121)
- Yingying Chen (ORCID: https://orcid.org/0000-0001-9162-1467)
- Ning Tian (ORCID: https://orcid.org/0000-0003-0491-278X)
- Haiyan Shi (ORCID: https://orcid.org/0000-0003-3473-1154)
- Xueying Kong (ORCID: https://orcid.org/0000-0002-6706-8005)
- He Ding (ORCID: https://orcid.org/0000-0002-2371-5119)
- Zufu Cheng
Institutions
- Chinese National Human Genome Center (CN)
- China Railway Shanghai Design Institute Group (China) (CN)
- Integrated Chinese Medicine (China) (HK)
- Foshan Hospital of TCM (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
- Guangzhou Chemistry (China) (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1652213
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09